BIOKIN PHARMACEUTICAL(SH:688506) Xin Lang Cai Jing·2025-10-21 06:36Group 1 - The core viewpoint of the news is the performance and financial metrics of Sichuan Baili Tianheng Pharmaceutical Co., Ltd., which saw a 5% increase in stock price, reaching 367.69 CNY per share, with a total market capitalization of 151.81 billion CNY [1] - The company was established on August 17, 2006, and went public on January 6, 2023, focusing on the research, production, and sales of pharmaceuticals [1] - The main business revenue composition indicates that 99.57% of revenue is recognized at a specific point in time, while 0.43% is recognized over a period [1] Group 2 - From the perspective of fund holdings, Dongzheng Asset Management has a fund that heavily invests in Baili Tianheng, with the top holding being the Oriental Red Medical Upgrade Stock Initiation A fund, which reduced its holdings by 93,200 shares in the second quarter [2] - The fund currently holds 478,600 shares, accounting for 10.05% of the fund's net value, with an estimated floating profit of approximately 8.38 million CNY [2] - The Oriental Red Medical Upgrade Stock Initiation A fund was established on March 29, 2022, with a latest scale of 481 million CNY, achieving a year-to-date return of 62.92% and a one-year return of 56.3% [2]